225 related articles for article (PubMed ID: 29672836)
1. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
[TBL] [Abstract][Full Text] [Related]
2. [Urachal cancer - current concepts of a rare cancer (German version)].
Reis H; Szarvas T
Pathologe; 2018 Dec; 39(Suppl 2):291-300. PubMed ID: 30470871
[TBL] [Abstract][Full Text] [Related]
3. Urachal cancer-current concepts of a rare cancer.
Reis H; Szarvas T
Pathologe; 2019 Jun; 40(Suppl 1):31-39. PubMed ID: 30895340
[TBL] [Abstract][Full Text] [Related]
4. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
5. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
Kim H; Kim BH; Lee D; Shin E
Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
[TBL] [Abstract][Full Text] [Related]
6. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
Riva G; Mian C; Luchini C; Girolami I; Ghimenton C; Cima L; Novelli L; Hanspeter E; Mazzoleni G; Schwienbacher C; Pycha S; D'Elia C; Trenti E; Pycha A; Martignoni G; Hes O; Eccher A; Nesi G; Brunelli M
Virchows Arch; 2019 Jan; 474(1):13-20. PubMed ID: 30302546
[TBL] [Abstract][Full Text] [Related]
7. KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status.
Polom K; Das K; Marrelli D; Roviello G; Pascale V; Voglino C; Rho H; Tan P; Roviello F
Pathol Oncol Res; 2019 Jan; 25(1):333-340. PubMed ID: 29116623
[TBL] [Abstract][Full Text] [Related]
8. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O
Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749
[TBL] [Abstract][Full Text] [Related]
9. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations.
Sirintrapun SJ; Ward M; Woo J; Cimic A
Hum Pathol; 2014 Feb; 45(2):327-30. PubMed ID: 24355196
[TBL] [Abstract][Full Text] [Related]
10. Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis.
Ye ZL; Qiu MZ; Tang T; Wang F; Zhou YX; Lei MJ; Guan WL; He CY
Cancer Med; 2020 Jan; 9(2):745-756. PubMed ID: 31782259
[TBL] [Abstract][Full Text] [Related]
11. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
[TBL] [Abstract][Full Text] [Related]
12. Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation.
Hartman DJ; Binion DG; Regueiro MD; Miller C; Herbst C; Pai RK
Inflamm Bowel Dis; 2018 Jul; 24(8):1780-1790. PubMed ID: 29788391
[TBL] [Abstract][Full Text] [Related]
13. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
[TBL] [Abstract][Full Text] [Related]
14. Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma.
Cornejo KM; Cosar EF; Paner GP; Yang P; Tomaszewicz K; Meng X; Mehta V; Sirintrapun SJ; Barkan GA; Hutchinson L
Int J Surg Pathol; 2020 Feb; 28(1):51-59. PubMed ID: 31496327
[No Abstract] [Full Text] [Related]
15. Prevalence of APC and PTEN Alterations in Urachal Cancer.
Nagy N; Reis H; Hadaschik B; Niedworok C; Módos O; Szendrői A; Bíró K; Hager T; Herold T; Ablat J; Black PC; Okon K; Tolkach Y; Csizmarik A; Oláh C; Keresztes D; Bremmer F; Gaisa NT; Kriegsmann J; Kovalszky I; Kiss A; Tímár J; Szász MA; Rink M; Fisch M; Nyirády P; Szarvas T
Pathol Oncol Res; 2020 Oct; 26(4):2773-2781. PubMed ID: 32754865
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
17. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
19. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
20. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
